Novartis: to acquire rights to antifungal agent
(CercleFinance.com) - Sandoz, Novartis' generics and biosimilars division, today announced that it has signed an agreement to acquire the worldwide rights to the systemic antifungal agent Mycamine (Funguard in Japan), from Astellas.
The group said that this will be an important addition to its growing portfolio of anti-infective therapies aimed at combating the spread of antimicrobial resistance by providing the right drug to the right patient at the right time.
Mycamine posted sales of 18.9 billion yen ($135m) for the year ended 31 March 2022. The transaction is expected to close in H1 2023, subject to standard conditions and regulatory approvals.
Copyright (c) 2023 CercleFinance.com. All rights reserved.